Discovering FRMD3: A Potential Drug Target Or Biomarker (G257019)

Target Name: FRMD3

NCBI ID: G257019

FRMD3

Discovering FRMD3: A Potential Drug Target Or Biomarker

FRMD3, FERM domain-containing protein 3 (isoform 2), is a protein that has been identified as a potential drug target or biomarker. It is a protein that is expressed in a variety of tissues, including the brain, heart, and kidneys, and is involved in the regulation of cellular processes that are important for both normal development and disease.

The discovery of FRMD3 comes from a research study conducted by a team of scientists at the University of California, San Diego. The study identified FRMD3 as a protein that is expressed in the brain and is involved in the regulation of the formation of new blood vessels. The researchers also found thatFRMD3 was overexpressed in a variety of diseases, including Alzheimer's disease, Parkinson's disease, and cancer.

FRMD3 is also known as FERM domain-containing protein 3 (isoform 2), which is a protein that contains a unique domain called the FERM domain. The FERM domain is a type of protein that is found in a variety of proteins and is involved in the regulation of cellular processes.

One of the key functions of FRMD3 is its role in the regulation of the formation of new blood vessels. This is important for many reasons, as the formation of new blood vessels is critical for the delivery of oxygen and nutrients to the brain, which is essential for maintaining brain health.

In addition to its role in blood vessel formation, FRMD3 is also involved in the regulation of many other cellular processes. For example, it is involved in the regulation of cell growth, differentiation, and apoptosis, which is the process by which cells die when they are no longer needed.

FRMD3 is also involved in the regulation of the immune system, which is important for protecting the body against infection and disease. The researchers have found that FRMD3 is involved in the regulation of T cell development and that it plays a role in the development of autoimmune diseases.

In addition to its role in the immune system, FRMD3 is also involved in the regulation of the blood-brain barrier, which is the barrier that separates the brain from the blood. This is important for maintaining the integrity of the brain and is critical for the delivery of oxygen and nutrients to the brain.

FRMD3 is also involved in the regulation of the nervous system, which is responsible for transmitting signals from the brain to the rest of the body. The researchers have found that FRMD3 is involved in the regulation of neurotransmitter release and that it plays a role in the development of neurodegenerative diseases.

In conclusion, FRMD3 is a protein that is involved in a variety of cellular processes that are important for both normal development and disease. The discovery of FRMD3 makes it an attractive target for drug research and may lead to new treatments for a variety of diseases. Further research is needed to fully understand the role of FRMD3 in cellular processes and to determine its potential as a drug target or biomarker.

Protein Name: FERM Domain Containing 3

Functions: Putative tumor suppressor gene that may be implicated in the origin and progression of lung cancer

The "FRMD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRMD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets